Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

NEW SILKROAD HOLDING GROUP LIMITED
新絲路控股集團有限公司
(formerly known as New Silkroad Culturaltainment Limited 新絲路文旅有限公司)
(Incorporated in Bermuda with limited liability)
(Stock Code: 472)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF AUDIT COMMITTEE, REMUNERATION COMMITTEE AND NOMINATION COMMITTEE

The board (the "**Board**") of directors (the "**Director(s)**") of New Silkroad Holding Group Limited (the "**Company**") is pleased to announce that Dr. Tsai Cheng Chieh ("**Dr. Tsai**") has been appointed by the Board as an independent non-executive Director and a member of each of the audit committee, the remuneration committee and the nomination committee of the Company, with effect from 8 May 2026.

The biographical details of Dr. Tsai are set out as follows:

Dr. Tsai, aged 41, obtained a Bachelor of Science in Agricultural Chemistry in 2008 from National Taiwan University, a Master of Science in Bioinformatics in 2010 from National Taiwan University and a Doctor of Philosophy in Pharmaceutical Sciences in 2019 from University of Maryland. He served as Chief of Staff at Kobin Real Estate Development Group from 2011 to 2014. He served as Director of Business Development of XtalPi in Boston from 2019 to 2024 and has served as Head of Strategic Execution, Vice President of Corporate Development of XtalPi in Boston since 2024 and was responsible for driving AI-powered corporate development and drug discovery initiatives across new energy, advanced materials, and agriculture sectors. Dr. Tsai is an expert in agriculture and AI sector.

Save as disclosed above, Dr. Tsai (i) did not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years prior to the date of this announcement; (ii) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iii) does not hold any other positions with other members of the Group.

As at the date of this announcement, Dr. Tsai does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Tsai has entered into a letter of appointment with the Company for a term of three years, which may be terminated by either party giving not less than one month's notice in writing served by either party to the other, subject to retirement by rotation and re-election at annual general meeting of the Company in accordance with the bye-laws of the Company. Pursuant to the terms of the service contract, he shall be entitled to an annual emolument of HK$180,000 which was determined by the Board based on the recommendation of the remuneration committee of the Company with reference to his qualification, duties and responsibilities within the Group.

Dr. Tsai has confirmed (a) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); (b) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (c) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there are no other matters concerning Dr. Tsai that need to be brought to the attention of the shareholders of the Company and there is no other information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to extend a warm welcome to Dr. Tsai for joining the Board.

By order of the Board
New Silkroad Holding Group Limited
Wang Gengyu
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 8 May 2026

As at the date of this announcement, the Board comprises Five executive Directors, namely, Mr. Wang Gengyu, Mr. Liu Huaming, Ms. Qiu Xuan, Mr. Hang Guanyu and Mr. Shen Yang, and Four independent non-executive Directors, namely Mr. Ting Leung Huel, Stephen, Mr. Chow On Kiu, Prof. Richard Gerardus Franciscus Visser and Dr. Tsai Cheng Chieh.